Accéder au contenu
Merck

IL-37 Expression Is Downregulated in Lesional Psoriasis Skin.

ImmunoHorizons (2020-11-27)
Kirsten Rønholt, Ane Langkilde-Lauesen Nielsen, Claus Johansen, Christian Vestergaard, Astrid Fauerbye, Rubèn López-Vales, Charles A Dinarello, Lars Iversen
RÉSUMÉ

IL-37 broadly suppresses inflammation in various disease models. However, studies of the regulation and role of IL-37 in psoriasis are limited and contradictive. Using transcriptome analysis, PCR, protein determination, and immunofluorescence, we demonstrated marked downregulation of IL-37 in biopsies from human lesional psoriasis skin compared with paired samples of nonlesional skin. Immunofluorescence analysis showed that IL-37 was localized to stratum granulosum of the epidermis. TNF-α stimulation of normal human epidermal keratinocytes led to increased IL37 expression through a p38 MAPK-mediated mechanism, whereas IL-17A, IL-17C, IL-17F, and IL-22 acted suppressively. Intradermal injection with recombinant human IL-37 into imiquimod-induced psoriasis skin of C57BL/6J mice demonstrated a trend toward a protective effect, however NS. Altogether, these results demonstrate that IL-37 is downregulated in human lesional psoriasis skin. This may be a consequence of the loss of stratum granulosum, but key cytokines in the development of psoriasis also seem to contribute to this downregulation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-IL37 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution